ERBB2 and lung cancer: It was previously demonstrated that in non‐small cell lung cancer cells, MET overexpression upregulated EGFR downstream signalling and the use of both EGFR/HER2 and MET tyrosine kinase inhibitors led to a maximal growth inhibition.49